Dinaciclib, as a potent inhibitor of CDK2, is assessed in phase III trial for chronic lymphocytic leukemia,[21] for advanced solid tumors in combination with veliparib (NCT01434316), for relapsed or refractory acute myeloid leukemia in combination with venetoclax (NCT03484520), phase I trial for advanced breast cancer in combination with pembrolizumab (NCT01676753). The gene discussed is CDK2; the disease is breast carcinoma.